The Women’s Tennis Association (WTA) has unveiled a new policy that will require all athletes competing on the women’s circuit to undergo a one‑time genetic test for the presence of the SRY gene, the biological marker that determines male sex. This measure, which is slated to take effect on Tuesday, is intended to create a uniform eligibility standard for participation in WTA events and to address ongoing concerns about gender classification in sport.
Under the revised eligibility framework, every player who wishes to enter a WTA tournament will be asked to submit a DNA sample that will be examined for the SRY gene. The SRY (sex‑determining region Y) gene is located on the Y chromosome and is responsible for initiating male sexual development during embryogenesis.
If the test confirms the absence of the SRY gene, the athlete will be deemed biologically female and therefore eligible to compete on the women’s tour. Conversely, if the gene is detected, the player will be classified as male and will be prohibited from participating in women’s events. The WTA has made clear that refusal to undergo the test will result in disciplinary action, including potential suspension or exclusion from competition.
The new rule replaces the organization’s previous approach to transgender inclusion, which allowed transgender women to compete provided they had publicly identified as female and had maintained testosterone levels below a specified threshold for a continuous period of two years. That earlier policy was designed to balance the rights of transgender athletes with concerns about competitive fairness, but it did not involve any direct genetic testing. The WTA’s latest move aligns its standards with those already adopted by World Athletics and the International Boxing Association, both of which introduced mandatory SRY testing for female athletes in 2025.
It is important to note that, as of now, there are no known transgender women competing on the WTA Tour at any professional level, nor are there any publicly identified cases of transgender participation in lower‑tier professional tennis circuits. Nonetheless, the association argues that establishing a clear, science‑based eligibility criterion is a proactive step to prevent future disputes and to ensure a level playing field for all competitors. In a formal statement, the WTA emphasized that the updated policy is meant to provide “a clear eligibility standard for participation in WTA tournaments.” The organization also highlighted that the testing process will be conducted with strict confidentiality and data‑privacy safeguards.
According to the statement, the screening will commence in 2026, after a comprehensive player‑engagement program has been rolled out to educate athletes about the new requirements, address concerns, and ensure that the implementation is handled with sensitivity. The WTA further acknowledged the complexity and sensitivity of the issue, pledging to treat all athletes with dignity and respect throughout the process.
The association underscored its commitment to applying the policy in a thoughtful manner, recognizing that gender identity and biological sex are topics that intersect with personal, medical, and social dimensions. Beyond the policy specifics, the announcement arrives at a time when the broader sports community is grappling with how to balance inclusion for transgender athletes with concerns about competitive equity. Critics of mandatory genetic testing argue that it may infringe on privacy rights and could be seen as discriminatory, while supporters claim that a clear biological benchmark is essential to maintain fairness in women’s sport. The WTA’s decision reflects a growing trend among international governing bodies to adopt genetic testing as a definitive method for confirming sex eligibility.
The rollout of the testing program will involve several logistical steps. First, the WTA will partner with accredited laboratories to process DNA samples securely. Athletes will be given detailed instructions on how to provide a sample, typically through a non‑invasive cheek swab or saliva collection. Once the sample is received, laboratory technicians will extract DNA and perform a polymerase chain reaction (PCR) assay specifically targeting the SRY gene.
The results, which will be binary—either the gene is present or absent—will be communicated directly to the athlete and to the WTA’s eligibility office. All data will be stored in encrypted databases, with access limited to authorized personnel to protect confidentiality.
In the event that an athlete tests positive for the SRY gene, the WTA has indicated that the player will be offered counseling and support services, as well as guidance on alternative pathways within the sport, such as coaching, officiating, or competing in mixed‑gender events where applicable. The organization also plans to establish an appeals process, allowing athletes to contest the results or request a review in cases where there may be procedural errors. The announcement also references the broader schedule of tennis in 2026, noting that the sport’s calendar will continue to feature the usual slate of Grand Slam tournaments, WTA 1000 and 500 events, and a full complement of regional competitions. While the policy change does not directly affect match scheduling or broadcasting arrangements—such as live coverage on Sky Sports or streaming options through NOW—it does represent a significant administrative shift that will be reflected in player registration forms and tournament entry protocols.
Overall, the WTA’s mandatory SRY testing policy marks a decisive move toward a more uniform and scientifically grounded definition of eligibility for women’s tennis. By instituting a one‑time genetic verification process, the organization aims to preempt disputes, safeguard the integrity of competition, and align itself with the standards set by other major sports federations.
As the sport progresses into 2026 and beyond, the impact of this policy will become clearer, both in terms of its effectiveness in maintaining competitive balance and its reception among athletes, advocates, and the broader public.